Rhein-Sieg-Kreis: Der Trend geht zur Briefwahl | Kölner Stadt-Anzeiger ksta.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksta.de Daily Mail and Mail on Sunday newspapers.
Rhein-Sieg-Kreis: Der Trend geht zur Briefwahl | Kölnische Rundschau rundschau-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rundschau-online.de Daily Mail and Mail on Sunday newspapers.
Rhein-Sieg: Viele Paare heiraten trotz Corona – oder erst recht ksta.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksta.de Daily Mail and Mail on Sunday newspapers.
Novartis Pharma AG: Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer 1 non-small cell lung cancer 2,3 help 1 beta (IL-1ß) in pro-tumor inflammation i n lung cancer, with multiple clinical trials investigating canakinumab in 2 -5 Basel, March 9, 2021 - Novartis announced today the Phase III CANOPY-2 study evaluating canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1ß), in combination with the chemotherapy agent docetaxel, did not meet its primary endpoint of overall survival (OS) 1. The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy